Xcout Intel
Apellis Pharmaceuticals, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Apellis Pharmaceuticals, Inc. among pharmaceuticals companies — ranked by similarity to what Apellis Pharmaceuticals, Inc. actually does, not by market-cap band.
Subscribe to see Apellis Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company headquartered in Waltham, Massachusetts. Founded in 2008, the public company discovers, develops, and commercializes targeted therapeutic treatments for autoimmune and inflammatory diseases.
Apellis Pharmaceuticals, Inc. at a glance
Apellis Pharmaceuticals, Inc. is a pharmaceuticals company headquartered in United States. It has raised at least $67.2M across the 2 funding rounds on record. Its most recent funding round raised $20M in August 2017. Xcout tracks 9 named people at Apellis Pharmaceuticals, Inc., including Cedric Francois (Co-Founder & Chief Executive Officer/President).
Apellis Pharmaceuticals, Inc. leadership
- Cedric FrancoisCo-Founder & Chief Executive Officer/President
- Alec MachielsCo-Founder
- Gerald ChanChairman
- Craig WheelerDirector
- Keli WalbertDirector
- Mikael DolstenDirector
3 more named people on record for Apellis Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Apellis Pharmaceuticals, Inc. funding rounds
At least $67.2M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $20M | — | |
| Series D | $47.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Apellis Pharmaceuticals, Inc. news
Top 12 Apellis Pharmaceuticals, Inc. competitors
Ranked by semantic similarity — how close each company is to Apellis Pharmaceuticals, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the exploration, advancement, and marketing of innovative therapies rooted in RNA interference (RNAi) technology. The company's research pipeline for RNAi treatments targets a diverse array of medical conditions, encompassing inherited disorders, cardiovascular and metabolic diseases, hepatic infections, and illnesses affecting the central nervous system (CNS) and eyes. Alnylam's commercialized products include ONPATTRO (patisiran), an injectable lipid complex prescribed for adults experiencing polyneuropathy due to hereditary transthyretin-mediated amyloidosis. Also marketed are GIVLAARI, used to treat acute hepatic porphyria (AHP) in adult patients, and OXLUMO (lumasiran), indicated for primary hyperoxaluria type 1 (PH1). In terms of its developmental programs, the company is progressing several candidates: Givosiran, for the treatment of AHP in adolescent patients. Patisiran, being investigated for transthyretin amyloidosis (ATTR amyloidosis) when accompanied by cardiomyopathy. Cemdisiran, aimed at complement-mediated diseases. ALN-AAT02, for liver disease associated with AAT deficiency. ALN-HBV02, targeting chronic hepatitis B virus infection. Zilebesiran, for the management of hypertension. ALN-HSD, for non-alcoholic steatohepatitis (NASH). Fitusiran, addressing hemophilia and various rare bleeding disorders. Inclisiran, developed to treat hypercholesterolemia. Lumasiran, for advanced PH1 and recurrent kidney stones. Vutrisiran, currently in Phase 3 clinical trials for ATTR amyloidosis. Alnylam Pharmaceuticals maintains strategic alliances with several key players in the industry. It collaborates with Regeneron Pharmaceuticals, Inc. on the discovery, development, and commercialization of RNAi therapeutics for ocular and CNS targets. Another significant partnership exists with Sanofi Genzyme, focusing on the broader development and commercialization of RNAi treatments. Furthermore, the company holds licensing and collaboration agreements with Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. The company was established in 2002 and operates from its headquarters in Cambridge, Massachusetts.
Similar pharmaceuticals company
Antares Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, focused on developing first-in-class precision medicines.
Similar pharmaceuticals company
EyePoint Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company developing and commercializing treatments for serious retinal diseases using sustained-release drug-delivery technologies. Its products and pipeline therapies serve patients with conditions such as uveitis and diabetic macular edema, primarily through ophthalmology and retina-care providers.
Similar pharmaceuticals company
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
Similar pharmaceuticals company
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Similar pharmaceuticals company
Ionis Pharmaceuticals, Inc. is a U.S.-based biotechnology company specializing in the discovery and development of RNA-targeted therapeutic agents. The company's commercialized portfolio features SPINRAZA, a treatment for spinal muscular atrophy (SMA) in both pediatric and adult patients. It also offers TEGSEDI, an injectable therapy for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, and WAYLIVRA, approved for familial chylomicronemia syndrome and familial partial lipodystrophy. Beyond its marketed therapies, Ionis is actively progressing numerous drug candidates through pivotal Phase 3 clinical trials. These late-stage programs include Eplontersen, a monthly self-administered subcutaneous injection targeting all types of TTR amyloidosis; Olezarsen, designed for patients with severe hypertriglyceridemia (SHTG); Donidalorsen, for hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis; Pelacarsen, for individuals with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, developed to inhibit superoxide dismutase 1 production. Furthermore, Ionis is exploring treatments across a broader spectrum of therapeutic areas, such as metabolic, infectious, renal, ophthalmic diseases, and cancer. The company maintains a significant strategic collaboration with Biogen Inc. and holds various collaboration and licensing agreements with other prominent pharmaceutical partners, including AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Founded in 1989, Ionis Pharmaceuticals, Inc. operates from its headquarters in Carlsbad, California.
Similar pharmaceuticals company
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
Similar pharmaceuticals company
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Similar pharmaceuticals company
Highlightll Pharma is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China. The firm focuses on the research and development of treatments for both peripheral and central autoimmune and inflammatory diseases.
Similar pharmaceuticals company
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
Medical - Pharmaceuticals
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Similar pharmaceuticals company
Egetis Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of treatments for serious, rare diseases with high unmet medical needs. Operating internationally, the public company has its headquarters in Stockholm, Sweden, alongside a growing presence in the United States. Its clinical pipeline targets specialized therapeutic indications to improve patient outcomes.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Apellis Pharmaceuticals, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Apellis Pharmaceuticals, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →